Single Port Robotic Lung Anatomical Resection

Chang Gung Memorial Hospital (Other)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

This is the first human clinical study for explore the feasibility of lung anatomic resection through Da Vinci SP surgical platform

Condition or Disease Intervention/Treatment Phase
  • Device: Lung Anatomic Resection (Da Vinci SP)

Detailed Description

During the past several years, minimally invasive thoracic surgery has evolved from thoracoscopic approaches using 3 -4 ports to a single incision video-assisted thoracoscopic surgery (VATS) techniques. Recently, the experience acquired with the uniportal VATS technique through the intercostal space has allowed the development of a uniportal VATS subxiphoid or subcostal approach for major pulmonary resections. The advantage of using a subxiphoid or subcostal entry is to reduce pain by avoiding possible trauma of intercostal nerves caused by thoracic incisions. However, the longer distance from the subxiphoid or subcostal incision to the hilum makes this approach more difficult to perform anatomical pulmonary resections.During this same period of evolution into uniportal VATS surgery, robotic thoracic surgery has gained popularity as an alternative to traditional VATS. The advantages of robotics are the ability to perform surgery more precisely with articulated or wristed instruments, motion scaling, and tremor filtration, as well as improved visualization thanks to 3D high-definition video. However, currently 4 -5 incisions are still necessary to perform anatomic robotic resections.Recently, there has been a convergence of these two trends-uniportal surgery and robotic-assisted surgery-and has resulted in a single port robotic system, the da Vinci SP by Intuitive Surgical Cooperation. For this new platform, investigators plan to practice in thoracic anatomic lung resection

Study Design

Study Type:
Anticipated Enrollment :
35 participants
Intervention Model:
Single Group Assignment
Intervention Model Description:
clinical lung cancer who receive Da Vinci sp robotic surgeryclinical lung cancer who receive Da Vinci sp robotic surgery
None (Open Label)
Primary Purpose:
Official Title:
Pilot Study of Single Port Robotic Surgery for Anatomical Lung Resection
Anticipated Study Start Date :
Sep 16, 2022
Anticipated Primary Completion Date :
Sep 15, 2023
Anticipated Study Completion Date :
Sep 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Da Vinci SP intervnetion group

for patients who received Da Vinci SP robotic surgery

Device: Lung Anatomic Resection (Da Vinci SP)
To evaluate the performance and safety of the da Vinci SP® Surgical System in anatomical lung resection

Outcome Measures

Primary Outcome Measures

  1. Incidence of conversion rate [During Surgery]

    The primary performance endpoint will be assessed as the ability to successfully complete the planned anatomic resection procedure with the da Vinci SP System, with no conversion to thoracoscopic, multi-port robotic, or open surgery. Usage of additional assistant port(s) is not considered a conversion.

Secondary Outcome Measures

  1. Incidence of Treatment Related Adverse Events [One Year]

    The primary safety endpoint will be assessed as the incidence of all intra-operative and post-operative adverse events that occur within the study follow-up period. Complications are assessed using the Common Terminology Criteria for Adverse Events, CTCAE.

  2. Peri-operative parameters [From Surgery to ward,2- day]

    Operation time (minute), docking time (minute), console time(minute), anesthesia time(minute), Time from recovery room to ward (minute)

  3. Peri-operative parameters: blood loss related [During surgery]

    which include bloods loss(ml) during operation, blood transfusion (ml) during surgery

  4. Hospitalization parameters [During Hospitalization, an average of 4 days]

    which include, length of hospital stay (day)

  5. Operative related complications during hospitalization [During Hospitalization, an average of 4 days]

    which include in-hospital mortality and morbidity, reasons need for reoperation, unplanned procedure after surgery

  6. Patient disposition immediately after surgery [During Hospitalization, an average of 1 day]

    ICU, ward

Other Outcome Measures

  1. 30-day follow-up [Post-operative data through 30-day follow-up]

    Complications (assed according to CTCAE)

  2. Questionnaire assessment [Through study completion, an average of 1 year]

    Enrolled subjects would be assessed by pain scale/numbness score at baseline (preoperatively), during inpatient phase. Neuropathic pain assessment (Assessment of post-VATS surgery neuralgia- pain DETECT Questionnaire), performed during inpatient phase (Post-operation 1 day, 2 days and day of discharge) and 1 week, 1,3,6,12 months after discharge.

  3. Questionnaire assessment [Through study completion, an average of 1 year]

    Enrolled subjects would be assessed by pain scale/numbness score at baseline (preoperatively), during inpatient phase. Quality of life assessment European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC-QOL-C30) , performed preoperatively, 1 week, 1,3,6,12 months after surgery.

  4. 90-day follow up (1) [Post-operative data through 90-day follow-up]

    Complications (assed according to CTCAE)

  5. Pathological Report [Post-operative data through 30-day follow-up]

    pathologic tumor staging, surgical margins

  6. 90-day Follow up (2) [Post-operative data through 90-day follow-up]

    Unplanned procedure-related reoperations or readmissions, mortality

Eligibility Criteria


Ages Eligible for Study:
20 Years to 75 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  1. Age >20 and <75 years-old

  2. Willing and able to provide informed consent

  3. ASA≤ 3

  4. The subject is undergoing the following procedures

  5. diagnosis with of clinical stage I lung cancer

  6. The primary tumor should be less than ≤4cm diameter and ≥ 2 cm away from the origin of the associated lobar bronchus

  7. Preoperative platelet count 150-400 (1000/ uL)

Exclusion Criteria:
  1. Congestive heart failure (NHYA > II)

  2. Subjects with a known bleeding or clotting disorder

  3. Subjects actively receiving therapeutic dose anticoagulation or anti-platelet medications at the time of operation

  4. Subjects under immunomodulatory or immunosuppressive regimen (e.g. transplant patient, steroid requirement) within 30 days prior to the planned surgery

  5. Subjects with pulmonary hypertension

  6. In need of extended resection (e.g. Chest wall, Carina, major vessel, bilobectomy) and reconstruction (e.g. Sleeve resection, bronchoplasty, angioplasty)

  7. Previous ipsilateral thoracic surgery or sternotomy

  8. Uncontrolled illness 6 months prior to planned surgical procedure including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  9. Previous neoadjuvant medical and/or radiation therapy

  10. Subject has a contraindication for general anesthesia or surgery

  11. Life expectancy < 6 months

  12. Anatomy determined intra-operatively to be unsuitable for minimally invasive surgery

  13. Subjects belong to vulnerable population (e.g., pregnancy or breastfeeding)

  14. International normalized ratio, INR >1.4

  15. Activated Partial Thromboplastin Time , APTT >35 -

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • Chang Gung Memorial Hospital


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Chang Gung Memorial Hospital Identifier:
Other Study ID Numbers:
  • 202101423A0
First Posted:
Sep 10, 2022
Last Update Posted:
Sep 10, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by Chang Gung Memorial Hospital

Study Results

No Results Posted as of Sep 10, 2022